475 GEN-011–101 (the TiTAN-1 trial): phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors

• Thomas Davis,
• Jessica Price,
• Arthur DeCillis,
• Richard Hernandez,
• Kevin Mancini,
• Craig Carey

Affiliations

Thomas Davis

Aff3 grid.417695.8Celldex Therapeutics, Inc. Charlottesville VA USA

Jessica Price

MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa

Arthur DeCillis

7Genocea Biosciences, Centreville, MD, USA

Richard Hernandez

7Genocea Biosciences, Centreville, MD, USA

Kevin Mancini

7Genocea Biosciences, Centreville, MD, USA

Craig Carey

Genocea, Centreville, MD, USA